Unité de Génétique des Biofilms, Département de Microbiologie, Institut Pasteur, Paris, France.
Antimicrob Agents Chemother. 2013 Aug;57(8):3960-8. doi: 10.1128/AAC.02606-12. Epub 2013 Jun 3.
Antivirulence strategies targeting bacterial behavior, such as adhesion and biofilm formation, are expected to exert low selective pressure and have been proposed as alternatives to biocidal antibiotic treatments to avoid the rapid occurrence of bacterial resistance. Here, we tested this hypothesis using group 2 capsule polysaccharide (G2cps), a polysaccharidic molecule previously shown to impair bacterium-surface interactions, and we investigated the nature of bacterial resistance to a nonbiocidal antibiofilm strategy. We screened an Escherichia coli mutant library for an increased ability to form biofilm in the presence of G2cps, and we identified several mutants displaying partial but not total resistance to this antibiofilm polysaccharide. Our genetic analysis showed that partial resistance to G2cps results from multiple unrelated mutations leading to modifications in surface physicochemical properties that counteract the changes in ionic charge and Lewis base properties induced by G2cps. Moreover, some of the identified mutants harboring improved biofilm formation in the presence of G2cps were also partially resistant to other antibiofilm molecules. This study therefore shows that alterations of bacterial surface properties mediate only partial resistance to G2cps. It also experimentally validates the potential value of nonbiocidal antibiofilm strategies, since full resistance to antibiofilm compounds is rare and potentially unlikely to arise in clinical settings.
针对细菌行为(如黏附和生物膜形成)的抗毒力策略预计会产生较低的选择压力,并被提议作为杀菌抗生素治疗的替代品,以避免细菌耐药性的快速出现。在这里,我们使用先前显示出可损害细菌-表面相互作用的多糖分子 2 组荚膜多糖(G2cps)来测试这一假设,并研究了细菌对非杀菌性抗生物膜策略产生耐药性的性质。我们筛选了大肠杆菌突变体文库,以研究在 G2cps 存在下形成生物膜的能力增加,发现了几个表现出部分但不是完全耐药的突变体。我们的遗传分析表明,对 G2cps 的部分耐药性是由多个不相关的突变导致的,这些突变改变了表面物理化学性质,抵消了 G2cps 诱导的离子电荷和路易斯碱性质的变化。此外,一些在 G2cps 存在下形成生物膜能力提高的鉴定突变体也对其他抗生物膜分子部分耐药。因此,这项研究表明,细菌表面特性的改变仅介导对 G2cps 的部分耐药性。它还通过实验验证了非杀菌性抗生物膜策略的潜在价值,因为对抗生物膜化合物的完全耐药性很少见,并且不太可能在临床环境中出现。